Tatiana L.
- Country
- Poland
- Department
- Centrum Medyczne PROMED
Research Overview
- Evaluation of Balcinrenone and Dapagliflozin on Cardiovascular Outcomes in Heart Failure Patients with Renal Impairment: A Phase III Randomized, Double-Blind Study
- Evaluation of Baxdrostat and Dapagliflozin on Chronic Kidney Disease Progression in Hypertensive Patients: A Randomized, Double-Blind, Active-Controlled Phase III Trial
- Efficacy and Safety of Baxdrostat and Dapagliflozin on Renal and Cardiovascular Outcomes in Chronic Kidney Disease with Hypertension
Data & Insights
Has run more than one trial at 117 of 442 partner sites.
Specializations
Kidney Disease Management
This investigator specializes in studying treatments for chronic kidney disease (CKD), particularly focusing on innovative therapeutic approaches to slow disease progression and improve patient outcomes.
- CKD progression monitoring
- Glomerular filtration rate assessment
- Renal function preservation
Their research includes evaluation of kidney function markers and sustained renal decline prevention strategies.
Cardiovascular Health
The investigator conducts research in cardiovascular medicine, with particular emphasis on heart failure management and its relationship with kidney function.
- Heart failure events
- Cardiovascular mortality
- Cardio-renal interactions
Their work encompasses cardiovascular outcomes in patients with combined cardiac and renal conditions.
Hypertension Research
The investigator focuses on blood pressure management in complex patient populations, particularly those with concurrent kidney disease.
- Hypertension control
- Combined therapy approaches
- Blood pressure regulation
Their research examines innovative therapeutic combinations for blood pressure control in chronic kidney disease patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.